Ann: Bodyguard Results, page-70

First 70 Last

Share
Profile

Follow
Padlock

5,988 Posts.

424

23/02/16

13:14

Post #: 17092589
Share
Originally posted by amg63 ↑

For me the biggest highlight of this announcement is the fact that anti-inflammatory drugs and creams can only be used for a limited time before it starts doing more harm than good to the body. With OBJ's natural ingredients we are able to achieve the same to even better results as the topical cream used in the trial which cannot be used for more than 2weeks unless a doctor advises. I also find it interesting that the USA market is mentioned. This to me the natural ingredient aspect has even greater knock on effects than outstanding results itself which we have achieved. If we can get P&G behind us and distribute the product, P&G's marketing department will have the easiest task on their hands to date! Implications of this trial may be missed by the market but the potential of this product is just out of this world, i'm sure the Goliath's will also acknowledge this.

Highlights:

Against the worlds largest selling topical non steroidal anti-inflammatory drug product

The clinical trial showed that Kneeguard, using OBJ’s all‐natural, drug‐free Lubricen formulation significantly improved physical function in individuals with a history of knee injury. It also reduced pain in this group to a greater degree than the comparator product.

An important secondary finding saw a significant improvement in the worst pain experienced over the past by patients using Kneeguard after just two weeks of usage

Importantly, this trial provides valuable data that a prospective partner will be able to use as Claims Support for any potential products launched

Topical NSAIDs are generally not suitable for use for more than 14 days, which is inappropriate for a degenerative condition that many will suffer for more than 20 years. OBJ’s approach of treating the underlying causes of joint pain using natural drug‐free ingredients provides a new means of managing joint degeneration in the long term while supporting healthy aging

In many countries (such as in the USA) topical anti‐inflammatory drugs are prescription only or available in limited quantities in order to limit the potential for adverse side effects.

The ingredients that power OBJ’s Lubricen formulation are all well characterised and have decades of established safety in humans. However the ability of these ingredients to compete directly against potent drugs has been limited by poor bioavailability Using OBJ’s proprietary through‐the‐skin delivery technology, Bodyguard was able to deliver effective amounts of these essential joint enhancement ingredients directly into the joint space, and in doing so, bypass first‐pass liver metabolism that until now has limited the efficacy of these ingredients.

OBJ is currently developing Bodyguard products for all the major joints of the body as well as wearable technology products for optimised local exercise preparation and recovery.

Expand

that's what I like

"developing BG products for all the major joints of the body"
OBJ Price at posting: 7.1¢ Sentiment: None Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

Failure to report prompts ASX to impose multiple company suspensions

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

IRE

Iress runs 'hot' for Wealth Within's stock tips

There are more pages in this discussion • 141 more messages in this thread...

First 70 Last

Add WFL (ASX) to my watchlist

(20min delay)
Last 0.3¢		Change 0.000(0.00%)		Mkt cap ! $1.478M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Ann: Bodyguard Results, page-70

Failure to report prompts ASX to impose multiple company suspensions

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Iress runs 'hot' for Wealth Within's stock tips

Featured News

Featured News

Ann: Bodyguard Results, page-70

Top Stories

Failure to report prompts ASX to impose multiple company suspensions

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Iress runs 'hot' for Wealth Within's stock tips

Featured News

Featured News